Autolus Therapeutics plc ADR (NASDAQ:AUTL) shares, rose in value on Friday, March 28, with the stock price up by 0.61% to the previous day’s close as strong demand from buyers drove the stock to $1.66.
Actively observing the price movement in the last trading, the stock closed the session at $1.65, falling within a range of $1.63 and $1.7. The value of beta (5-year monthly) was 2.064. Referring to stock’s 52-week performance, its high was $6.44, and the low was $1.56. On the whole, AUTL has fluctuated by -5.14% over the past month.
With the market capitalization of Autolus Therapeutics plc ADR currently standing at about $441.76 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-19.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 1.42M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AUTL’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of AUTL currently trading nearly -9.13% and -15.48% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 38.45, while the 7-day volatility ratio is showing 5.00% which for the 30-day chart, stands at 7.38%. Furthermore, Autolus Therapeutics plc ADR (AUTL)’s beta value is 2.05, and its average true range (ATR) is 0.12.
A comparison of Autolus Therapeutics plc ADR (AUTL) with its peers suggests the former has fared considerably weaker in the market. AUTL showed an intraday change of 0.61% in last session, and over the past year, it shrunk by -73.10%%.
Data on historical trading for Autolus Therapeutics plc ADR (NASDAQ:AUTL) indicates that the trading volumes over the past 10 days have averaged 1.29 and over the past 3 months, they’ve averaged 1.22 million. According to company’s latest data on outstanding shares, there are 266.13 million shares outstanding.
Nearly 9.70% of Autolus Therapeutics plc ADR’s shares belong to company insiders and institutional investors own 53.77% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 9.13 million shares as on 2025-03-14, resulting in a short ratio of 7.04. According to the data, the short interest in Autolus Therapeutics plc ADR (AUTL) stood at 452.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 9.49 million. The stock has fallen by -29.36% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AUTL stock heading into the next quarter.
